CD95-induced apoptosis in human liver disease

Seminars in Liver Disease

Volumn 18, Issue 2, 1998, Pages 141-151

  Galle, Peter R ^a   Krammer, Peter H ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Acute hepatic failure; Alcoholic hepatitis; Cytotoxic T cells; Immune privilege; Viral hepatitis

Indexed keywords

FAS ANTIGEN;

ALCOHOL LIVER DISEASE; APOPTOSIS; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; LIVER CELL; LIVER DISEASE; LIVER FAILURE; PRIORITY JOURNAL; VIRUS HEPATITIS;

EID: 0031950395     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007150     Document Type: Article

References (90)

1. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-1449
2. Nagata S, Golstein P. The Fas death factor. Science 267:1995; 1449-1456
3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462
4. Alderson MR, Armitage RJ, Maraskovsky E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993;178:2231-2235
5. Marpara MY, Bargou R, Zugck C, et al. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with Bcl-2 oncogene expression. Eur J Immunol 1993;23:702-708
6. Aggarwal BB, Singh S, LaPushin R, Totpal K. Fas antigen signals proliferation of normal human diploid fibroblasts and its mechanism is different from tumor necrosis factor receptor. FEBS Lett 1995;364:5-8
7. Freiberg RA, Spencer DM, Choate KA, et al. Fas signal transduction triggers either proliferation or apoptosis in normal human fibroblasts. J Invest Dermatol 1997;108:215-219
8. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827
9. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover J Cell Biol 1996;133:335-343
10. Leithäuser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the NGF/TNF receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-429
11. Ni R, Tomita Y, Matsuda K, et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes Exp Cell Res 1994;215: 332-337
12. Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the APO-1/Fas (CD95) receptor and ligand in liver damage J Exp Med 1995;182:1223-1230
13. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and in the liver. Nat Genet 1995;11:294-300
14. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a member of the tumor necrosis factor family. Cell 1993;75:1169-1178
15. Mariani SM, Matiba B, Bäumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995;25:2303-2307
16. Apasov S, Redegeld F, Sitkovsky M. Cell-mediated cytotoxity; contact and secreted factors. Curr Opin Immunol 1993;5:404-410
17. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through Perform and Fas Iytic pathways. Nature 1994;370:650-652
18. Kägi D, Ledermann B, Bürki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in Perforin-deficient mice. Nature 1994;369:31-37
19. Kägi D, Vignaux F, Ledermann B, et al. Fas and Perform pathways as major mechanisms of T-cell-mediated cytotoxicity. Science 1994;265:528-530
20. 2+-independent T cell-mediated cytotoxicity. J Exp Med 1993;177: 195-200
21. Gilette-Ferguson I, Sidman CL. A specific intercellular pathway of apoptotic cell death is defective in the mature peripheral T cells of autoimmune 1pr and g1d mice. Eur J Immunol 1994; 24:1181-1185
22. Hanabuchi S, Koyanagi M, Kawasaki A, et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1994;91:4930-4934
23. Ju ST, Cui H, Pauka DJ, et al. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 1994;91:4185-4189
24. Stalder T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T-cell mediated cytotoxicity Immunol 1994; 152:1127-1133
25. Vignaux F, Golstein P. Fas-based lymphocyte-mediated cytotoxicity against syngerieic activated lymphocytes: A regulatory pathway? Eur J Immunol 1994;24:923-927
26. Alderson MR, Tough TW, Davis Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-77
27. Dhein J, Walczak H, Bäumler C, et al. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature 1995;373:438-441
28. Brunner T, Mogil RJ, LaFace D, et al. Cell autonomous Fas (CD95/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441-444
29. Ju ST, Panka DJ, Cui H, et al. Fas (CD95)FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-448
30. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-632
31. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 17:1189-1192
32. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;273:109-112
33. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-1082
34. Hahne M, Rimoldi D, Schröter M, et al. Melanoma cell expression of Fas (APO-1/CD95) ligand: Implications for tumor immune escape. Science 1996;274:1363-1366
35. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells: A mechanism of immune evasion? Nat Med 1996;2:1361-1367
36. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on island beta cells induces a granulocytic infiltration but does not confere immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997;94:3943-3947
37. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165-170
38. Harris CC. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 1996;17:1187-1198
39. Harris CC. Structure and function of the p53 tumor suppressor gene clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-1455
40. Volkmann M, Hofmann WJ, Müller M, et al. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994; 9:195-204
41. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996;6:12-19
42. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-16
43. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311
44. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-7495
45. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-teleangiectasia. Cell 1992;71:587-597
46. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852
47. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993;82:1092-1096
48. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362: 847-849
49. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis. p53-dependent and independent pathways. Oncogene 1995;11:199-210
50. Lee ML, Bernstein A. Apoptosis, cancer and the p53 tumor suppressor gene. Cancer Metastasis Rev 1995;14:149-161
51. Barak Y, Juven T, Haffner R, Oren M. Mdm2 expression is induced by wildtype p53 acivity. EMBO J 1993;12:461-468
52. Chen CY, Oliner JD, Zhan Q, et al. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994;91:2684-2688
53. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825
54. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994;266:1376-1380
55. Müller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of p53 J Clin Invest 1997;99:403-413
56. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wildtype human p53 and a temperature-sensitive mutant induce FAS/APO-1 expression. Mol Cell Biol 1995;15:3032-3040
57. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer chemoresistance Curr Opin Oncol 1995;7: 541-546
58. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of Bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986;83:5214-5218
59. Que FG, Gores GJ. Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996;110:1238-1243
60. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994;145:1323-1336
61. Lacronique V, Mignon A, Fabre M, et al. Bcl-2 protects from lethal hepatic apoptosis induced by an antiFas antibody in mice. Nat Med 1996;2:80-86
62. Rodriguez I, Matsuura K, Khatib K, et al. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by antiFas antibody injection. J Exp Med 1996;183:1031-1036
63. Zhao M, Zhang N-X, Economou M, et al. Immunohistochemical detection of Bcl-2 protein in liver lesions: Bcl-2 protein is expressed in hepatocellular carcinomas but not in liver dysplasia. Histopathology 1994;25:237-245
64. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-317
65. Watanabe-Fukunaga R, Brannan CI, Itoh N, et al. The cDNA structure, expression and chromosomal assignement of the mouse Fas antigen. J Immunol 1992;148:1274-1279
66. Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 1993;90:1756-1760
67. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-977
68. Adachi M, Suematsu S, Suda T, et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 1996;93:2131-2136
69. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-946
70. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-1349
71. Le Deist F, Emile JF, Rieux-Laucat F. et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 1996;348:719-723
72. Ando K, Moriyama T, Guidotto L, et al. Mechanisms of class 1 restricted immunopathology. A transgenic mouse model of fulminant hepatitis J Exp Med 1993;178:1541-1554
73. Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995;22:1316-1325
74. Kondo T, Suda T, Fukuyama H, et al Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;3:409-413
75. Kerr JFR, Cooksley WGE, Searl J, et al. The nature of piecemeal necrosis in chronic active hepatitis. Lancet 1979;2:827-828
76. Searl J, Harmon BV, Bishop CJ, Kerr JFR. The significance of cell death by apoptosis in hepatobiliary disease. J Gastroenterol Hepatol 1987;2:77-96
77. Schulte-Hermann R, Grasl-Kraupp B, Bursch W. Apoptosis and hepatocarcinogenesis In Jirtle RL (ed): Liver Regeneration and Carcinogenesis New York, Academic Press; 1995
78. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (antiFas) to cell surface antigen codownregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-1756
79. Takahashi H, Kobayashi H, Hashimoto Y, et al. Interferongamma dependent stimulation of Fas antigen in SV40-transformed human keratinocytes: Modulation of the apoptotic process by protein kinase C. J Invest Dermatol 1995;105:810-815
80. Mochizuki K, Hayashi N, Hiramatsu N, et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 1996;24:1-7
81. Hiramatsu N, Hayashi N, Katayama K, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994;19:1354-1359
82. Mita E, Hayashi N, Iio S, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Com 1994;204:468-474
83. Hug H, Strand S, Grambihler A, et al. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem 1997;272:28191-28193
84. Rouquet N, Pages JC, Molina, et al. ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Curr Biol 1996;6:1192-1195
85. Rodriguez I, Matsuura K, Ody C, et al. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 1996;184:2067-2072
86. Terada T, Nakanuma Y. Detection of apoptosis and expression of apoptosis-related proteins during intrahepatic bile duct development. Am J Pathol 1995;146:67-74
87. Kuroki T, Seki S, Kawakita N, et al. Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Virchows Arch 1996;429:119-129
88. Higaki K, Yano H, Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 1996;149:429-437
89. Shimizu M, Yoshimoto T, Nagata S, Matsuzawa A. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Biochem Biophys Res Commun 1996;228:375-379
90. Badley AD, McElhinny JA, Leibson PJ, et al. Upregulation of Fas ligand expression by human immunodeficient virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996;70:199-206